Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/22 10:00:13 pm
125.03 USD   -0.10%
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNS : Acclarent Unit in $18 Million U.S. Settlement
07/21 JOHNSON & JOHNS : DePuy Synthes Announces Agreement with Materialise..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2012 | 11:51pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/21 JOHNSON & JOHNSON : DePuy Synthes Announces Agreement with Materialise for 3D-Pr..
07/21 JOHNSON & JOHNSON : tops 2Q forecasts despite profit drop
07/21 Unilever sharpens P&G rivalry by buying Dollar Shave Club
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : J&J rises on Wall St. beat, lifts forecast
07/20DJJOHNSON & JOHNSON : Jury Acquits Former Johnson & Johnson Unit Executives of Fel..
07/20 JOHNSON & JOHNSON : Announces Quarterly Dividend for Third Quarter 2016
07/20 Johnson & Johnson Reports 2016 Second-Quarter Results
More news
Sector news : Pharmaceuticals - NEC
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21DJBIOGEN : CEO to Step Down; Reports Upbeat Earnings, Outlook--Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 6 MONTH PORTFOLIO UPDATE : Good News, Double-Digit Increase In Both Income And V..
07/22 DOMINION RESOURCES INC. : An Income Utility Company For The Future But At A Rich..
07/22 JOHNSON & JOHNSON : 3 Reasons To Be Optimistic From The Q2 Results
07/22 Healthcare ratings - upgrades/downgrades
07/21 UNILEVER AND DOLLAR SHAVE CLUB : Delivering A Close, Uncomfortable Shave For Pro..
Advertisement
Financials ($)
Sales 2016 72 055 M
EBIT 2016 21 649 M
Net income 2016 16 531 M
Finance 2016 14 348 M
Yield 2016 2,51%
P/E ratio 2016 21,23
P/E ratio 2017 18,84
EV / Sales 2016 4,57x
EV / Sales 2017 4,29x
Capitalization 343 913 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 0,40%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
BRISTOL-MYERS SQUIBB C..10.02%126 333
More Results